Literature DB >> 218727

Insulin and glucagon receptors in Morris hepatomas of varying growth rates.

V Pezzino, R Vigneri, M D Siperstein, I D Goldfine.   

Abstract

The binding of both insulin and glucagon to receptors in plasma membranes from five hepatomas of varying growth rates was diminished when compared to plasma membranes from normal liver. Scatchard analyses of the binding data suggested that the decrease in glucagon binding was due to a decrease in binding capacity, whereas the decrease in insulin binding was due either to a decrease in binding affinity or to site-site interactions. The decreased binding of insulin, but not of glucagon, showed a significant correlation with increasing growth rate of the tumors. These data suggest, therefore, that decreased binding of insulin to receptors could be a feature of increasing growth rate in hepatomas.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218727

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 2.  Primary hepatocellular carcinoma. Present state of the disease and prospects for the future.

Authors:  C J Oon; M A Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Glucagon resistance of hepatoma cells. Evidence for receptor and post-receptor defects.

Authors:  M Fehlmann; M Crettaz; C R Kahn
Journal:  Biochem J       Date:  1983-09-15       Impact factor: 3.857

4.  A comparison of lipids from liver and hepatoma subcellular membranes.

Authors:  R Wood; G C Upreti; R J deAntueno
Journal:  Lipids       Date:  1986-04       Impact factor: 1.880

5.  Insulin receptors in human cancer.

Authors:  E A Benson; I M Holdaway
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.